Catalog No.: PC-20310Not For Human Use, Lab Use Only.
T-1101 tosylate (TAI-95 tosylate) is a potent, orally abioavailable Hec1 inhibitor that disrupts Hec1-Nek2 protein interaction wide anti-cancer spectrum (GI50=14.29-73.65 nM, breast cancer cell lines).
T-1101 tosylate (TAI-95 tosylate) is a potent, orally abioavailable Hec1 inhibitor that disrupts Hec1-Nek2 protein interaction wide anti-cancer spectrum (GI50=14.29-73.65 nM, breast cancer cell lines).
T-1101 tosylate demonstrates strong inhibition of in vivo tumor growth of breast cancer models without inducing weight loss or other obvious toxicity.
T-1101 tosylate induces apoptotic cell death, shows activity on MDR cell lines and leads to downregulation of the expression of P-glycoprotein (Pgp),.
T-1101 tosylate also increases the potency of cytotoxic Pgp substrates, including doxorubicin and topotecan.
T-1101 tosylate showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7), as well as of breast cancer (BT474, MDA-MB-231, and MCF7) with oral administration.
